This common problem is called solar purpura, and it is largely the sun causing the damage to the skin, thinning it with age.

Insmed invests heavily in a robust pipeline with multi-billion potential, positioning for future growth. Check out why INSM ...

A laryngologist explains the surprising causes of chronic throat clearing, including silent reflux, allergies and muscle ...

The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

Learn the essential facts about fungal sinus infections, from recognizing early warning signs to understanding treatment ...

Researchers have developed and preliminarily tested a composite score that simultaneously assesses the severity of asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) in patients with both ...

Tezepelumab was linked to significantly reduced nasal polyp size and nasal congestion vs placebo in adults with severe CRSwNP.

Learn more about whether Alvotech or Recursion Pharmaceuticals, Inc. is a better investment based on AAII's A+ Investor ...

Sanofi and Regeneron's Dupixent (dupilumab) has gained approval from the FDA for chronic spontaneous urticaria (CSU) ...

Aclaris Therapeutics, Inc.’s ACRS share price has surged by 10.08%, which has investors questioning if this is right time to sell.

Sanofi reports amlitelimab improved lung function in asthma, with new phase 3 trials planned across its respiratory pipeline.

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and ...